141 related articles for article (PubMed ID: 18230353)
1. The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes.
Hasegawa G; Kajiyama S; Tanaka T; Imai S; Kozai H; Fujinami A; Ohta M; Obayashi H; Park H; Nakano K; Tanaka M; Shiraishi E; Fukui M; Yoshikawa T; Nakamura N
Clin Chim Acta; 2008 Apr; 390(1-2):110-4. PubMed ID: 18230353
[TBL] [Abstract][Full Text] [Related]
2. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
[TBL] [Abstract][Full Text] [Related]
3. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
[TBL] [Abstract][Full Text] [Related]
4. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes.
Ogawa S; Takeuchi K; Ito S
Diabetes Obes Metab; 2004 Sep; 6(5):384-90. PubMed ID: 15287932
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
6. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
7. Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Nakamura K; Yamagishi S; Matsui T; Inoue H
Drugs Exp Clin Res; 2005; 31(4):155-9. PubMed ID: 16223205
[TBL] [Abstract][Full Text] [Related]
8. Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance.
Inoue I; Shinoda Y; Nakano T; Sassa M; Goto S; Awata T; Komoda T; Katayama S
Metabolism; 2006 Jul; 55(7):946-52. PubMed ID: 16784969
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of alpha-glucosidase inhibition in the management of diabetes.
Bischoff H
Clin Invest Med; 1995 Aug; 18(4):303-11. PubMed ID: 8549017
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
Zeymer U
Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
[TBL] [Abstract][Full Text] [Related]
11. Acarbose, an alpha-glucosidase inhibitor for non-insulin-dependent diabetes.
Welborn TA
Med J Aust; 1998 Jan; 168(2):76-8. PubMed ID: 9469188
[No Abstract] [Full Text] [Related]
12. [Reducing postprandial glucose levels. Glucosidase antagonists].
Neye H
Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
[No Abstract] [Full Text] [Related]
13. [Changes in metabolic parameters and microalbuminuria in patients with type 2 diabetes treated with acarbose].
González Sarmiento E; Ergueta Martín P; Fernández Martínez I; Hinojosa Mena-Bernal MC; Zurro Muñoz I; Zurro Hernández J
An Med Interna; 2001 May; 18(5):234-6. PubMed ID: 11496556
[TBL] [Abstract][Full Text] [Related]
14. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs.
Rudofsky G; Reismann P; Schiekofer S; Petrov D; von Eynatten M; Humpert PM; Isermann B; Müller-Hoff C; Thai TP; Lichtenstein S; Bärtsch U; Hamann A; Nawroth P; Bierhaus A
Horm Metab Res; 2004 Sep; 36(9):630-8. PubMed ID: 15486815
[TBL] [Abstract][Full Text] [Related]
15. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
Azuma K; Toyofuku Y; Iesaki T; Otsuka A; Tanaka A; Mita T; Hirose T; Tanaka Y; Daida H; Kawamori R; Watada H
Biochem Biophys Res Commun; 2006 Jun; 345(2):688-93. PubMed ID: 16696939
[TBL] [Abstract][Full Text] [Related]
16. [Acarbose (glucobai) effects on lipid metabolism in patients with non-insulin dependent diabetes mellitus].
Rosliakova LV; Roĭtman AP; Ametov AS; Dolgov VV
Ter Arkh; 2000; 72(8):54-6. PubMed ID: 11019430
[TBL] [Abstract][Full Text] [Related]
17. Starch digestion, large-bowel fermentation and intestinal mucosal cell proliferation in rats treated with the alpha-glucosidase inhibitor acarbose.
Dehghan-Kooshkghazi M; Mathers JC
Br J Nutr; 2004 Mar; 91(3):357-65. PubMed ID: 15005821
[TBL] [Abstract][Full Text] [Related]
18. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
Laakso M
Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
[No Abstract] [Full Text] [Related]
19. Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome.
Tuğrul S; Kutlu T; Pekin O; Bağlam E; Kiyak H; Oral O
Fertil Steril; 2008 Oct; 90(4):1144-8. PubMed ID: 18377903
[TBL] [Abstract][Full Text] [Related]
20. Alpha-glucosidase inhibitors may reduce the risk of type 2 diabetes.
Servey JT
Am Fam Physician; 2007 Aug; 76(3):374-5. PubMed ID: 17708136
[No Abstract] [Full Text] [Related]
[Next] [New Search]
